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2. Materials and methods 
Abstract It has previously been suggested that the mammary 
cell could produce prolactin (PRL). This hypothesis was 
investigated by incubation with [ S]methionine-cysteine followed 
by SDS-PAGE, immunoblotting and autoradiography of im-
munoprecipitated PRL, and by electron microscopic analysis 
after incubation without or with cycloheximide. Immunoreactive 
14-, 23-, 25-, 32- and 36-kDa PRL forms were radioactive. By 
two-dimensional electrophoresis analysis, immunoreactive and 
radioactive spots, of about 25 kDa and high molecular weight, 
were also detected. After incubation of mammary epithelial cells 
with cycloheximide, immunogold electron microscopy showed a 
drastic decrease of labelling in organdies involved in synthesis 
and secretion, compared to those incubated in control medium. 
These results make it possible to conclude that lactating 
mammary tissue is able to synthesize PRL. 
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1. Introduction 
Prolactin (PRL), first discovered in the pituitary gland, is 
now thought to be produced in a variety of mammalian tis-
sues [1-5]. The P R L m R N A has been observed in several cell 
types [6-9], including mammary epithelial cells (MEC) of lac-
tating rat, goat, sheep and rabbit [10-13] and of normal and 
neoplastic tissue [14]. Newly synthesized P R L has been de-
tected in a breast cancer cell line [15]. However, P R L synthesis 
in lactating mammary tissue has never been reported until 
now. P R L detected in the milk has been considered a pituitary 
plasma-borne P R L . This hormone is carried across the M E C 
[16,17] and transferred into milk in a variety of bioactive and 
immunoreactive variants [18-20]. In lactating M E C , P R L was 
located inside the organdies involved in endocytosis and also 
in synthesis and exocytosis. When rats were injected with bro-
mocriptine, the labeling was shown to increase in the later 
compartments and to decrease in the endocytic region. Sub-
sequently, it was suggested that P R L located in the M E C 
could be of two origins [21]. 
The goal of this study was to elucidate whether lactating 
M E C synthesize P R L . Two approaches were used. First, new-
ly synthesized proteins were labeled in vitro to detect newly 
synthesized P R L after immunoprecipitation. Second, mam-
mary tissues were incubated in the absence or presence of 
cycloheximide, an inhibitor of protein synthesis, then intracel-
lular localization of the hormone was carried out by immu-
nogold electron microscopy. 
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2.1. Animal treatments 
Female Wistar rats on day 14 of lactation, weighing 180-250 g, 
originating from our laboratory, were used for all experiments. All 
animal experiments were conducted in accordance with the highest 
standards of care, as outlined in the NIH guide for the care and 
use of laboratory animals. 
To compare between control and bromocriptine-treated rats, one 
group (control) received the drug vehicle only. The second group was 
injected subcutaneously with 800 μg of bromocriptine (CB 154 from 
Sandoz, Hanover), twice daily (9 h, 17 h) for 3 days and the 4th day, 
30 min before decapitation. 
2.2. Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from the mammary gland, muscle and 
pituitary gland using a modified version of the guanidinium-phenol 
method [22]. 
The sequences of primers actin 1 corresponding to positions 2746-
2767 (exon 5): 5'-CATCCGTAAAGACCTCTATGCC-3' and actin 2 
to positions 3019-3039 (exon 6): 5'-TAGAGCCACCAATCCACA-
CAG-3' were deduced from the rat gene encoding cytoplasmic ß-actin 
(accession number V01217). Primers PRL1: 5'-TGTTCTGGTGGC-
GACTGCCA-3' and PRL2: 5'-TATCTTTTCGATCCCTTCGAGA-
AGCCG-3' correspond to primers of rPRL-A (exon 2) and rPRL-C 
(exon 4), respectively, used by [4]. Oligonucleotides were provided by 
Oligoexpress (Paris, France). 
Reverse transcription reactions were carried out using 2.5 μg of 
total RNA of mammary gland or muscle or 0.5 μg of pituitary total 
RNA in the presence of 1 X RT buffer (Gibco-BRL Life Technologies, 
Cergy-Pontoise, France), 1 mM DTT, 2 mM of each dNTP and 40 
units RNasin (Promega, France). Reactions were primed with 10 mM 
oligo(dT) by incubating for 1 h at 37°C in the presence of 200 units of 
superScript II reverse transcriptase (Gibco-BRL) which was subse-
quently inactivated by heating at 95°C for 5 min. The reaction mix 
was then adjusted to 50 μΐ with distilled water. 
PCR amplification was performed in 50 μΐ essentially as described 
[23], with buffer and Taq DNA polymerase supplied by Promega. For 
actin DNA amplification, after the initial denaturing step (94°C for 
5 min), 25 cycles of amplification were performed: 40 s at 94°C, 40 s 
at 60°C and 40 s at 72°C. For PRL DNA amplification, after the 
initial denaturing step (94°C for 40 s), 35 cycles of amplification 
were performed: 40 s at 94°C, 40 s at 55°C, 45 s at 72°C. 20 μΐ of 
each reaction mix were fractionated in a 3% agarose TBE 1 X slab gel 
in the presence of ethidium bromide (0.5 μΐ/ml). 
2.3. Incubation and metabolic labeling 
Mammary fragments were obtained after removing fat and connec-
tive tissues (weight of each fragment 0.1-0.2 mg; total weight 2 g). 
After washing and 30 min of preincubation in Hanks' medium (Gib-
co-BRL), at 37°C, atmosphere 95% 0 2 +5% C0 2 , the fragments were 
incubated in methionine and cysteine-free RPMI medium (Gibco-
BRL) for 45 min at 37°C, rinsed extensively with the same medium, 
then labeled for 45 min at 37°C with Pro-Mix [35S] Cell labeling mix 
(85 μ θ per ml, Amersham, UK). Mammary fragments were then 
extensively washed and homogenized as described below. 
In order to deprive the fragments of circulating PRL and to inhibit 
protein synthesis, fragments were preincubated for 30 min in Hanks' 
medium, rinsed extensively, then incubated 3 times (30 min each) in 
RPMI medium or in RPMI containing 0.35 mM cycloheximide (Sig-
ma Chemical Co., St. Louis, MO). After each 30 min incubation, the 
medium was replaced by a fresh one. At the end of incubation, frag-
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ments were treated for immunogold electron microscopy as described 
below. 
To verify the effect of cycloheximide on protein synthesis, metabolic 
labeling was carried out in the presence of this inhibitor. Briefly, 
following a 30 min preincubation in Hanks' medium, fragments 
were incubated for 45 min with methionine and cysteine-free RPMI 
medium in the presence or absence of 0.35 mM cycloheximide, then 
labeled for 45 min with Pro-Mix [35S] (85 μ θ per ml) in the presence 
or absence of 0.35 mM cycloheximide. Radioactivity of trichloracetic 
acid precipitated proteins was counted as described in [16]. 
2.4. Preparation of tissue extracts and immunoprecipitation 
Each gram of tissue was homogenized in 1 ml of 10 mM HEPES, 
150 mM NaCl, pH 7.5, containing a protease inhibitor cocktail (apro-
tin, pepstatin A, leupeptin, chymostatin and antipain 2 μg/ml final 
each; Sigma). The homogenate was spun at 600 Xg for 15 min at 
4°C. After adding 50 μΐ of 10% Triton X-100, the supernatants under-
went three cycles of freeze-thawing and were centrifuged in a Beck-
man TL100 Ultracentrifuge at 100 000 Xg for 30 min at 4°C, to elim-
inate casein micelles which could be pelleted during immuno-
precipitation. 
Immunoprecipitation was carried out as described in [21]. Briefly, 
each supernatant supplemented with solubilizing buffer (1 v:l v) was 
incubated with 2 μΐ preimmune rabbit serum and 50 μΐ protein A 
sepharose, then the mixture was centrifuged at 15 800 X g. The super-
natant was incubated with 3 μΐ anti-rPRL antiserum IC-5 (generously 
supplied by The National Hormone and Pituitary Program, NIDDK) 
for 12 h at 4°C, then with 40 μΐ of protein A sepharose for 90 min at 
room temperature. Beads were washed with appropriate buffers. After 
centrifugation at 15 800Xg for 1 min, proteins attached to beads were 
solubilized in 50 μΐ of Laemmli sample buffer and supernatants were 
pooled. Proteins were analyzed by SDS-PAGE or two-dimensional 
electrophoresis followed by immunoblotting and autoradiography. 
2.5. SDS-PAGE and immunoblotting analysis 
Samples were resolved by SDS-PAGE in 15% gel under reducing 
conditions, and transferred to nitrocellulose membrane (Schleicher & 
Schüll, Keene, NH). Membranes were saturated and incubated for 2 h 
with anti-rPRL antiserum at 1:1000, then incubated for 60 min with 
peroxidase-conjugated monoclonal anti-rabbit IgG (γ-chain specific; 
1:500; Sigma), after washing. Proteins were revealed using an en-
hanced chemiluminescence detection kit (Amersham, UK). 
2.6. Two-dimensional electrophoresis 
Proteins obtained by immunoprecipitation were precipitated with 
cold acetone, then solubilized in lysis buffer. Samples were analyzed 
by two-dimensional electrophoresis performed basically according to 
[24]. They were first subjected to isoelectric focusing in the presence of 
9.5 M urea capillary gels containing 2.5% of ampholines pH 3.5-5, 
2.5% of ampholines pH 5-7 and 2% of ampholines pH 3.5-9.5. The 
pH gradient in capillaries showed a range of 4.35-6.95. After isoelec-
tric focusing, capillary gels were incubated in equilibration buffer 
(0.062 M Tris-HCl pH 6.8; 2.3% SDS; 5% ß-mercaptoethanol and 
10% glycerol) then subjected to electrophoresis in the second dimen-
sion in 12.5% gel. 
Nitrocellulose filters from SDS-PAGE and two-dimensional electro-
phoresis followed by immunoblotting left for one night at 4°C, were 
washed and dried, then exposed to a BioMax film (Kodak, New 
York) at -80°C. 
2.7. Immunogold electron microscopy 
Mammary fragments were fixed in 2% paraformaldehyde-0.1 M 
sodium cacodylate buffer, dehydrated with ethanol and embedded in 
Unicryl (Tebu, France). Thin sections were processed for immunogold 
labeling (see [21]) using anti-rPRL antiserum (1:100) and gold-conju-
gated anti-rabbit IgG (1:300). Control sections were treated similarly 
using a nonimmune rabbit serum or with omission of primary anti-
body. 
Mammary tissues from two animals in each group (control and 
bromocriptine-treated group) were used to quantify the PRL labeling 
in the MEC. In each experiment, ultrathin sections of standard thick-
ness (~80 nm) from mammary tissue incubated in the absence or 
presence of cycloheximide were processed in pairwise fashion during 
immunogold labeling. The number of gold particles (G) and their 
distribution (%G) were counted on micrographs taken at random at 
the same magnification (X 10000). At this low magnification, different 
cellular compartments were illustrated on each micrograph. Forty 
micrographs (20 from each control rat) and 20 micrographs (10 
from each bromocriptine-treated rat) were used. The area of cellular 
compartments (P) was evaluated by spot numbering [25]. 
3. Results 
3.1. Detection of PRL mRNA in the mammary tissues from 
control and bromocriptine-treated rats 
Total R N A prepared from lactating rat mammary tissue, 
muscle and pituitary gland was reverse transcribed and am-
plified using primers complementary to nucleotides of actin 
and P R L genes. Fig. IB shows that the signal corresponding 
to P R L was detected in mammary tissue from control and 
bromocriptine-treated animals. The size of amplified frag-
ments generated using primers PRL1 and PRL2 was in agree-
ment with the size for the full-length 23 k D a P R L m R N A 
previously described [4] and was identical to those amplified 
from the pituitary gland. 
A comparison of the amount of amplified fragments from 
different control and bromocriptine-treated rats is given in 
Fig. 1. This showed that, while the amount of amplified frag-
ments using actin primers remained identical for all the sam-
ples from mammary tissues (Fig. 1A), the amount of amplified 
fragments corresponding to PRL transcripts was variable de-
pending on the animal (Fig. IB). 
3.2. In vitro synthesis of PRL in lactating rat mammary tissue 
To verify whether P R L m R N A present in these mammary 
tissues could be translated to express the protein, mammary 
fragments were labeled with Pro-Mix [35S], homogenized and 
immunoprecipitated with ant i - rPRL antiserum. As revealed 
by immunoblott ing, immunoreactivity was associated with 
protein bands of 14, 23, 25, 32 and 42 k D a (Fig. 2A). It 
must be noted that the immunodetectable band corresponding 
to the 25-kDa form was always more intense than the 23-kDa 
band. The 14- and 23-kDa forms were more or less detectable 
or not detectable, depending on the animal. 
Autoradiography performed on the same nitrocellulose fil-
ters showed radioactive bands which superimposed exactly 
onto the 14-, 23-, 25-, 32-, and 42-kDa immunoreactive bands. 
Radioactivity associated with these forms of PRL strongly 
suggested that PRL was synthesized during the labeling. Im-
munoprecipitates were further analyzed by two-dimensional 
electrophoresis followed by immunoblott ing and autoradio-
Table 1 
Effect of cycloheximide treatment on the distribution of gold parti-
cles, in cellular compartments of MEC from control rats 
1 2 3 4 5 6 
A 
B 
%P 
G 
%G 
%P 
G 
%G 
3 
20 
4.7 
6.3 
17 
12.2 
3.4 
72 
17 
2.8 
39 
28 
14.7 
68 
16.1 
15 
29 
20.8 
16.1 
204 
48.3 
16.6 
33 
23.7 
3.9 
28 
6.6 
7.3 
19 
13.7 
7.5 
30 
7.1 
1 
2 
1.4 
MEC were incubated in the absence (A) or presence of cycloheximide 
(B). The distribution of gold particles was counted on 20 micrographs 
per rat. %P, Percentage of the cell area occupied by each compart-
ment; G, number of gold particles in each compartment; %G, per-
centage of total grains. 1, Endocytic region; 2, endosomes plus multi-
vesicular bodies; 3, nucleus; 4, rough endoplasmic reticulum; 5, Golgi 
apparatus; 6, secretory vesicles. Values from two animals. 
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Fig. 1. Detection of PRL transcripts from the mammary gland of 
lactating rat. Total RNA, extracted from muscle (lane 1), mammary 
tissue from two control rats (lanes 2 and 3) and two bromocriptine-
treated rats (lanes 4 and 5), pituitary gland (lane 6), was subjected 
to RT-PCR using either primers actin 1 and actin 2 (A), or primers 
PRL1 and PRL2 (B). Amplified fragments were stained with ethi-
dium bromide. The size of the single fragments (in bp) generated by 
PCR is indicated on the right and of molecular standards (line M) 
on the left. 
graphy to eliminate the risk of contamination by other newly 
synthesized proteins. Fig. 3A showed that PRL of about 25 
kDa and high molecular weight forms were immunologically 
detectable. Autoradiography of the nitrocellulose filter re-
vealed that these forms were also radioactive (Fig. 3B). In 
these conditions the 14- and 23-kDa forms were not detect-
able. It could be supposed that the very low quantities of 
these forms of PRL, always smaller than the 25-kDa form, 
make it impossible to detect them by two-dimensional electro-
phoresis. 
Samples from homogenized and immunoprecipitated tissue 
previously incubated with cycloheximide did not shown any 
immunoreactive or radioactive band (not shown). 
Specificity of the PRL detection with anti-rPRL IC5 in 
tissue extracts and immunoprecipitates was checked as pre-
viously described [21]. 
3.3. In vitro effect of cycloheximide on the localization of 
PRL in mammary epithelial cells 
As attested by the radioactivity of total tissue precipitable 
proteins measured after metabolic labeling in the presence or 
absence of cycloheximide, protein synthesis was inhibited by 
Fig. 3. Two-dimensional electrophoresis analysis of immunoprecipi-
tated rPRL from mammary tissue labeled with Pro-Mix [35S] label. 
A: Immunoblot with anti-rPRL antiserum. * : cold PRL added to 
the sample. B: Autoradiogram of the same nitrocellulose membrane. 
Arrowhead indicates 35S-labeled spots which are immunoreactive. 
Fig. 2. SDS-PAGE analysis of immunoprecipitated rPRL from 
mammary tissue labeled with Pro-Mix [35S] label. A: Immunoblot 
detection with anti-rPRL antiserum. Lane 1: Standard rPRL-B6. 
Lane 2: Tissue extract. B: Autoradiogram of the same nitrocellulose 
membrane. Arrowhead indicates 35S-labeled bands which are immu-
noreactive. Molecular mass markers are indicated on the left. 
95% (radioactivity was 132 728 cpm/mg of tissue incubated in 
control medium and 6400 cpm/mg of tissue incubated in medi-
um containing cycloheximide). 
After incubation in the presence of cycloheximide, the mor-
phological aspect of the MEC was modified as attested by the 
relative volume (% P) of cell compartments (Table 1). Golgi 
stacks were swollen and very few secretory vesicles were ob-
served. Consequently, the relative volume of these organelles 
was considerably decreased. This observation revealed that in 
the absence of protein synthesis, very few secretory vesicles 
were present in the cell. 
Immunogold labeling showed that, after incubation in the 
absence (Fig. 4a,c) or presence (Fig. 4b,d) of cycloheximide, 
MEC were faintly labeled. To quantify the intracellular PRL 
distribution in organelles of MEC, the percentage of the total 
gold particles was expressed in the following compartments: 
basolateral membranes and endosomes close to the basolat-
eral membrane considered as the endocytic region; endosomes 
plus multivesicular bodies; nucleus; rough endoplasmic reti-
culum (RER); Golgi apparatus and secretory vesicles. It ap-
peared clearly that in MEC incubated in the presence of cy-
cloheximide, the total number of gold particles was lower than 
in MEC incubated in the control medium (139 versus 422; see 
Table 1). This phenomenon was particularly noticeable in 
RER and secretory vesicles but also in nucleus, in Golgi ap-
paratus and in endosomes plus multivesicular bodies. The 
distribution of gold particles indicated the same decrease of 
labeling in RER and secretory vesicles and revealed a concen-
tration in basolateral membrane, in endosomes plus multives-
icular bodies. 
When MEC from bromocriptine-treated rats were incu-
bated in the absence or presence of cycloheximide, a large 
decrease of the relative volume of secretory vesicles containing 
casein micelles was observed. In addition, vesicles empty of 
any electron dense material accumulated in the cell (Fig. 
5a,b). These were counted separately and designated 'non-
identified vesicles'. There was no difference in the total num-
ber of gold particles with or without cycloheximide (Table 2). 
However, the number of gold particles counted in MEC in the 
presence of the inhibitor was decreased in RER, secretory 
vesicles, nucleus and Golgi apparatus and was increased in 
endosomes plus multivesicular bodies. The category of 'non-
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Fig. 4. Immunogold electron microscopy localization of rPRL in MEC from control rats, incubated in the absence (a and c) or presence of cy-
cloheximide (b and d). a: Gold particles are located in RER (arrowhead), b : After incubation with cycloheximide, very few gold particles are 
located in RER. c: Secretory vesicles, containing filamentous material and casein micelles, are labeled, d: After incubation with cycloheximide, 
Golgi stacks are swollen, Golgi vesicles are faintly labeled. RER, rough endoplasmic reticulum; GA, Golgi apparatus; SV, secretory vesicle. 
Bar = 0.2 μpiι. 
identified vesicles' was also labeled. The distribution of gold 
particles confirmed the decrease of labeling of RER and se-
cretory vesicles when protein synthesis was inhibited. Unex-
pectedly, distribution of labeling increased in endosomes plus 
multivesicular bodies but was not modified in the basolateral 
region. 
4. Discussion 
This study strongly supports the hypothesis that the MEC 
are able to synthesize PRL during lactation. Detection of PRL 
mRNA in mammary tissue, from control or bromocriptine-
treated rats, is in accordance with previous reports [10-13]. 
Although the RT-PCR realized were not quantitative, results 
obtained with amplified PRL and actin fragments, taken to-
gether, suggest an individual variability. Subsequently, no re-
lationship between the level of circulating PRL and the 
amount of PRL mRNA could be established. This variability 
was also reported in other species [12,13]. 
Detection of radioactive proteins related to PRL immuno-
precipitated after metabolic labeling revealed a synthesis of 
PRL. This immunoreactive and radioactive PRL was detected 
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in 14-, 23-, and 25-kDa forms, in addition to some high mo-
lecular weight forms. Molecular variants of PRL have been 
widely reported in pituitary, serum and milk (for review see 
[26]). The pituitary 25-kDa form has been described as a gly-
cosylated variant [27,28]. The newly synthesized PRL reported 
in breast cancer cell lines has been described as multiple gly-
cosylated species [15]. It can be postulated that lactating MEC 
are also able to synthesize a glycosylated form. Moreover, 
synthesis of PRL as a 23-kDa form by lymphoid cells has 
been reported [5]. In the hypothalamic-neurohypophyseal sys-
tem, synthesis of the 23-kDa form of PRL and its processing 
into a 14-kDa fragment has also been described [4]. Since 
mammary tissue is able to cleave plasma-borne PRL [29,30], 
the present results suggest that a similar processing of newly 
synthesized PRL occurs in MEC. 
High molecular weight forms could correspond to oligo-
meric PRL complexes, which have been widely reported 
among species (for review see [26]). Mena et al. [31] studying 
phosphorylated PRL have observed a 45-kDa form in two-
dimensional electrophoresis under reducing conditions. In 
lymphoid cells, in addition to the 23-kDa form, a 36-kDa 
form has been described as newly synthesized PRL [5]. How-
ever, in these cells as in present work, radioactive molecules 
not immunologically related to PRL were also observed after 
immunoprecipitation. It could correspond to no specific ad-
sorption of proteins. 
After incubation, few PRL remained immunocytochemi-
cally detectable in these cells (10% of the hormone detected 
in lactating cells without incubation [21]). Cycloheximide led 
to a drastic decrease of labeling in organelles involved in 
synthesis and exocytosis, in both MEC from control and bro-
mocriptine-treated rats, confirming the role of the MEC in the 
synthesis of the hormone. Unexpectedly, persisting labeling 
remained on the basal membrane. 
As shown by morphological observation of mammary tis-
sues, after incubation in the presence of cycloheximide, the 
number of secretory vesicles was strongly decreased. Contin-
uous secretory protein synthesis could be very important for 
the formation of secretory vesicles. In mammary tissues from 
bromocriptine-treated rats inhibition of protein synthesis in-
duced morphological modifications resulting in the accumula-
tion of numerous empty vesicles. Since in these experimental 
conditions plasma-borne PRL was strongly reduced by bro-
mocriptine and since no PRL cannot be synthesized by the 
cell because of the inhibition of protein synthesis, we may 
wonder whether these morphological modifications are related 
to the very low level of PRL. 
Table 2 
Effect of cycloheximide treatment on the distribution of gold-labeled 
PRL, in cellular compartments of MEC from bromocriptine-treated 
rats 
A 
B 
%P 
G 
%G 
%P 
G 
%G 
1 
6.1 
55 
10.7 
5.3 
47 
11.3 
2 
2.6 
73 
14.2 
3.4 
145 
34.8 
3 
11.4 
91 
17.8 
8.3 
55 
13.2 
4 
16.8 
233 
45.5 
13.2 
117 
28 
5 
2.6 
34 
6.6 
2.2 
25 
6 
6 
4.6 
26 
5 
0.8 
3 
0.7 
7 
_ 
-
-
9 
25 
6 
MEC were incubated in the absence (A) or presence of cycloheximide 
(B). The distribution of gold particles was counted on 10 micrographs 
per rat. P, G and cellular compartments as in Table 1. In addition, 7, 
non-identified vesicles. Values from two animals. 
Fig. 5. Immunogold electron microscopy localization of PRL in 
MEC from bromocriptine-treated rats, incubated in the absence (a) 
or presence of cycloheximide (b). a: After incubation in control 
medium, secretory vesicles containing filamentous material and case-
in micelles and small Golgi vesicles are labeled, b: After incubation 
in the presence of cycloheximide, vesicles empty of electron dense 
material accumulate (*). Small vesicles in the Golgi apparatus re-
gion were labeled. E, endosome-like vesicle; GA, Golgi apparatus; 
SV, secretory vesicle. Bar = 0.2 μpiι. 
The synthesis of PRL by MEC raises questions about the 
functional implication of this production. It is well known 
that MEC is a target for PRL which regulates transcription 
of milk protein genes [32], and exerts a secretagogue effect 
[33]. In these conditions, how could production of PRL by 
the MEC be of importance for the physiology of the cell? 
Autocrine or 'intracrine' effects of PRL regarded as a local 
growth factor have been hypothesized since proliferation of 
mammary cell line was inhibited by neutralization of newly 
synthesized PRL [34]. It was reported that the glycosylated 
form of PRL has the same or less bioactive potency than the 
standard form (for review see [26]). Moreover, the 14-kDa 
form of PRL synthesized by the hypothalamus presents mito-
genic and lactogenic potencies [29] and anti-angiogenic effects 
[35]. The question whether processing of PRL in the MEC can 
convert the hormone into bioactive products is raised. Such a 
phenomenon has been described in the case of the propara-
thyroid hormone related peptide which is processed intracel-
lularly to a more active product [36]. 
On the other hand, a role of the maternal PRL, carried by 
the milk, on the development of the neonate has been sug-
gested [37]. The ability of the MEC to produce PRL in var-
ious forms may be a way of ensuring a supply of hormone in 
milk to the neonate when the maternal plasma-borne PRL 
level is very low. 
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